Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer

European Journal of Cancer

Volumn 46, Issue 8, 2010, Pages 1382-1391

  Retèl, Valesca P ^a   Joore, Manuela A ^b,c   Knauer, Michael ^a,d   Linn, Sabine C ^a   Hauptmann, Michael ^a   Harten, Wim H van ^a,e  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d University Teaching Hospital Feldkirch   (Austria)

^e UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

70 Gene MammaPrint signature; Breast cancer; Cost effectiveness; Gene expression profiling

Indexed keywords

ANASTROZOLE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; LETROZOLE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS SOFTWARE; DIAGNOSTIC TEST; DISTANT METASTASIS; DRUG COST; HUMAN; MULTIPLE CYCLE TREATMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CANCER STAGING; COST BENEFIT ANALYSIS; DISEASE COURSE; ECONOMICS; FEMALE; GENETICS; MORTALITY; PROCEDURES;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FEMALE; HUMANS; MARKOV CHAINS; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 77951938304     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.02.035     Document Type: Article

References (36)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
2. Mook S., Van't Veer L.J., Rutgers E.J., et al. Individualisation of therapy using Mammaprint: from development to the MINDACT trial. Cancer Genomics Proteomics 4 (2007) 147-155
3. Van't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
4. van de Vijver M.J., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 (2002) 1999-2009
5. Buyse M., Loi S., van't Veer L.J., et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98 (2006) 1183-1192
6. Bueno-de-Mesquita J.M., Linn S.C., Keijzer R., et al. Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat (2008)
7. Bueno-de-Mesquita J.M., van Harten W., Retel V., et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol 8 (2007) 1079-1087
8. Bogaerts J., Cardoso F., Buyse M., et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol 3 (2006) 540-551
9. Retel V.P., Bueno-de-Mesquita J.M., Hummel M.J., et al. Constructive Technology Assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnostics. Int J Technol Assess Health Care 25 (2009) 73-83
10. Oestreicher N., Ramsey S.D., Linden H.M., et al. Gene expression profiling and breast cancer care: what are the potential benefits and policy implications?. Genet Med 7 (2005) 380-389
11. Hornberger J., Cosler L.E., and Lyman G.H. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care 11 (2005) 313-324
12. Lyman G.H., Cosler L.E., Kuderer N.M., et al. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 109 (2007) 1011-1018
13. Goldhirsch A., Wood W.C., Gelber R.D., et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18 (2007) 1133-1144
14. Ravdin P.M., Siminoff L.A., Davis G.J., et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19 (2001) 980-991
15. Bueno-de-Mesquita J.M., Sonke G.S., van de Vijver M.J., and Linn S.C. Additional value and potential use of the 70-gene prognosis signatura in node-negative breast cancer in daily clinical practice. Ann Oncol (2009)
16. Goldhirsch A., Ingle J.N., Gelber R.D., et al. Threshold for therapies: highlights of the Sankt Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20 (2009) 1319-1329
17. Yamashita H., Nishio M., Toyama T., et al. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res 6 (2004) R24-R30
18. Keefe D.L. Trastuzumab-associated cardiotoxicity. Cancer 95 (2002) 1592-1600
19. Dunkler D., Michiels S., and Schemper M. Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis?. Eur J Cancer 43 (2007) 745-751
20. Goldhirsch A., Glick J.H., Gelber R.D., et al. Meeting highlights: international consensus panel on the treatment of primary breast cancer. Seventh international conference on adjuvant therapy of primary breast cancer. J Clin Oncol 19 (2001) 3817-3827
21. Lidgren M., Jonsson B., Rehnberg C., et al. Cost-effectiveness of HER2 testing and 1-year adjuvant Trastuzumab therapy for early breast cancer. Ann Oncol 19 (2008) 487-495
22. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. N Engl J Med 354 (2006) 809-820
23. Dutch National Center for Health Statistics, Centraal Bureau voor de Statistiek DH (in Dutch). Available at: http://statline.cbs.nl/StatWeb/publication/?VW=T&DM=SLNL&PA=7052_95&D1=0-1,7,30-31,34,38,42,49,56,62-63,66,69-71,75,79&D2=0& D3=0&D4=a,!0-28&HD=080509-0829&HDR=G2,G1,G3&STB=T.
24. Lidgren M., Wilking N., Jonsson B., et al. Health related quality of life in different states of breast cancer. Qual Life Res 16 (2007) 1073-1081
25. Oostenbrink J.B., Koopmanschap M.A., and Rutten F.F.H. Manual for cost analyses, methods and standard prices for economic evaluations in health care. Amstelveen (The Netherlands): Dutch Health Insurance Executive Board (2006) (in Dutch)
26. Health Care Insurance Board. Pharmacotherapeutic Compass (in Dutch), 2006; Amstelveen. Available at: http://www.fk.cvz.nl.
27. Weinstein M.C. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 24 (2006) 1043-1053
28. Fenwick E., Claxton K., and Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 10 (2001) 779-787
29. Earle C.C., Coyle D., and Evans W.K. Cost-effectiveness analysis in oncology. Ann Oncol 9 (1998) 475-482
30. Tengs T.O., and Wallace A. One thousand health-related quality-of-life estimates. Med Care 38 (2000) 583-637
31. Kurian A.W., Thompson R.N., Gaw A.F., et al. A cost-effectiveness analysis of adjuvant Trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol 25 (2007) 634-641
32. Garrison Jr. L.P., Lubeck D., Lalla D., et al. Cost-effectiveness analysis of Trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer 110 (2007) 489-498
33. Liberato N.L., Marchetti M., and Barosi G. Cost-effectiveness of adjuvant Trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 25 (2007) 625-633
34. Retel V.P., Joore M.A., and van Harten W.H. Scenario drafting as a tool to perform early cost-effectiveness analysis. The case of the 70-gene signature in breast cancer. International Health Economic Association (2009), Beijing, China
35. Knauer M, Cardoso F, Mook S, et al. Identification of a low risk subgroup in HER2-positive breast cancer by the 70-gene prognosis signature. San Antonio Breast Cancer Conferences, 2008.
36. Mook S., Schmidt M.K., Viale G., et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 116 (2009) 295-302